Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Square Pharmaceuticals has a quick ratio of 11.57. It generally indicates good short-term financial strength.
The historical rank and industry rank for Square Pharmaceuticals's Quick Ratio or its related term are showing as below:
DHA:SQURPHARMA'
s Quick Ratio Range Over the Past 10 Years
Min: 3.56 Med: 9.86 Max: 15.77
Current: 11.57
During the past 13 years, Square Pharmaceuticals's highest Quick Ratio was 15.77. The lowest was 3.56. And the median was 9.86.
DHA:SQURPHARMA's Quick Ratio is ranked better than 95.69% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.4
vs DHA:SQURPHARMA: 11.57
Square Pharmaceuticals (DHA:SQURPHARMA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Square Pharmaceuticals Quick Ratio Related Terms
Square Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:SQURPHARMA vs ZTS, UTHR: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Square Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Square Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Square Pharmaceuticals's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) has a Quick Ratio of 11.57 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Square Pharmaceuticals and its competitors. This is 17% above median its historical median of 9.86. Over the past decade, Square Pharmaceuticals' Quick Ratio has ranged from 3.56 to 15.77. According to the industry distribution chart, Square Pharmaceuticals ranks #43 out of 997 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Square Pharmaceuticals' Quick Ratio too high?
Square Pharmaceuticals' current Quick Ratio of 11.57 is 17% above median its 10-year median of 9.86. Over the past 10 years, this metric has ranged from a low of 3.56 to a high of 15.77. The Drug Manufacturers industry median Quick Ratio is 1.40. Square Pharmaceuticals' value of 11.57 is 726.4% above this industry median. Based on the distribution chart, Square Pharmaceuticals ranks #43 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Square Pharmaceuticals ranks #43 out of 997 companies for Quick Ratio. This places Square Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.40. Square Pharmaceuticals' value of 11.57 is 726.4% above this benchmark. Historically, Square Pharmaceuticals' own Quick Ratio has ranged from 3.56 to 15.77 over the past decade. While the company's 10-year median is 9.86 vs. the industry median of 1.40, Square Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.40, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Square Pharmaceuticals's current Quick Ratio of 11.57 is 726.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Square Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Square Pharmaceuticals's current Quick Ratio is 11.57, which is 17% above median its own 10-year median of 9.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current Quick Ratio is 11.57, which is 17% above median its 10-year median of 9.86 and 726.4% above the Drug Manufacturers industry median of 1.40. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current Quick Ratio is 11.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96.
GuruFocus considers Square Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:SQURPHARMA:
Quick Ratio: 11.57 (17% above median its 10-year median of 9.86)
GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
Industry Position: 726.4% above the Drug Manufacturers median (#43 of 997)
No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score
Get the complete analysis for DHA:SQURPHARMA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SQURPHARMA has been successfully added to your 
